Kv1.1 channels of dorsal root ganglion neurons are inhibited by n-butyl-p-aminobenzoate, a promising anesthetic for the treatment of chronic pain.
In this study, we investigated the effects of the local anesthetic n-butyl-p-aminobenzoate (BAB) on the delayed rectifier potassium current of cultured dorsal root ganglion (DRG) neurons using the patch-clamp technique. The majority of the K(+) current of small DRG neurons rapidly activates and slowly inactivates at depolarized voltages. BAB inhibited the whole-cell K(+) current of these neurons with an IC(50) value of 228 microM. Dendrotoxin K (DTX(K)), a specific inhibitor of Kv1.1, reduced the DRG K(+) current at +20 mV by 34%, consistent with an important contribution of channels incorporating the Kv1.1 subunit to the delayed rectifier current. To further investigate the mechanism of BAB inhibition, we examined its effect on Kv1.1 channels heterologously expressed in mammalian tsA201 cells. BAB inhibits the Kv1.1 channels with an IC(50) value of 238 microM, similar to what was observed for the native DRG current. BAB accelerates the opening and closing of Kv1.1, but does not alter the midpoint of steady-state activation. BAB seems to inhibit Kv1.1 by stabilizing closed conformations of the channel. Coexpression with the Kv beta 1 subunit induces rapid inactivation and reduces the BAB sensitivity of Kv1.1. Comparison of the heterologously expressed Kv1.1 and native DRG currents indicates that the Kv beta 1 subunit does not modulate the gating of the DTX(K)-sensitive Kv1.1 channels of DRG neurons. Inhibition of the delayed rectifier current of these neurons may contribute to the long-duration anesthesia attained during the epidural administration of BAB.
Beekwilder
J P
JP
Department of Physiology, Leiden University Medical Center, Leiden, The Netherlands.
O'Leary
M E
ME
van den Broek
L P
LP
van Kempen
G Th H
GT
Ypey
D L
DL
van den Berg
R J
RJ
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000779:Anesthetics, Local / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001566:Benzocaine / Q000031:analogs & derivatives* / Q000494:pharmacology*; D002478:Cells, Cultured; D002908:Chronic Disease; D005727:Ganglia, Spinal / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D051662:Kv1.1 Potassium Channel; D051379:Mice; D009474:Neurons / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D010146:Pain / Q000188:drug therapy*; D026902:Potassium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D015221:Potassium Channels / Q000502:physiology*; D024642:Potassium Channels, Voltage-Gated
D000779:Anesthetics, Local; C496946:KCNA1 protein, human; C496947:Kcna1 protein, mouse; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D051662:Kv1.1 Potassium Channel; C004605:butamben; D001566:Benzocaine